About one in five women diagnosed with breast cancer already have an underactive thyroid before starting chemotherapy, suggesting thyroid issues are common in this group even before treatment begins.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine the pooled prevalence of pre-diagnosed hypothyroidism in breast cancer populations across diverse settings and ethnicities.
A systematic review and meta-analysis of all prospective studies reporting baseline hypothyroidism prevalence in breast cancer patients at diagnosis, including at least 25 studies with >10,000 total participants, stratified by age, region, and screening practices.
An RCT could test whether screening and treating subclinical hypothyroidism at diagnosis improves outcomes, but cannot establish baseline prevalence.
An RCT randomizing 1,000 breast cancer patients to universal thyroid screening and treatment versus standard care, measuring fatigue, weight gain, and quality of life, but not designed to estimate baseline prevalence.
A prospective cohort could confirm the prevalence of hypothyroidism at diagnosis and track its stability over time.
A multicenter prospective cohort of 1,000 newly diagnosed breast cancer patients, with TSH and free T4 measured at diagnosis and every 3 months for 12 months, to determine baseline prevalence and natural history.
A case-control study could compare hypothyroidism prevalence in breast cancer patients versus healthy controls to assess association.
A matched case-control study comparing 500 breast cancer patients to 500 age-matched healthy women, measuring TSH and thyroid antibodies at enrollment to determine if hypothyroidism is more common in cancer patients.
A cross-sectional study could estimate the prevalence of hypothyroidism in a single cohort of breast cancer patients at one time point.
A single-center survey of 1,000 breast cancer patients at diagnosis, measuring TSH and free T4 to estimate prevalence of clinical and subclinical hypothyroidism.